Dicerna Pharmaceuticals, Inc.
Pagina dedicata companiei Dicerna Pharmaceuticals, Inc. listata cu simbolul US.DRNA
Descriere companie[edit | ]
Dicerna Pharmaceuticals Inc (www.dicerna.com) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.
Grafic actiuni companie[edit | ]